How should hormone therapy for castration-resistant prostate cancer be continued?

被引：0

作者：

Spahn, M. ^{[1
]}

Krebs, M. ^{[1
]}

机构：

[1] Univ Klin Wurzburg, Klin & Poliklin Urol & Kinderurol, D-97080 Wurzburg, Germany

来源：

UROLOGE | 2012年 / 51卷 / 01期

关键词：

Hormone therapy; Prostate cancer; Castration resistance; Androgen deprivation; Metastatic progression; PHASE-II; ANTIANDROGEN WITHDRAWAL; CLINICAL-TRIALS; WORKING GROUP; ANTIGEN; TESTOSTERONE; CHEMOTHERAPY; EXPRESSION; RECOMMENDATIONS; MITOXANTRONE;

D O I：

10.1007/s00120-011-2738-9

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but still androgen-sensitive tumor growth. Our understanding and the treatment of such castration-resistant prostate cancer has changed markedly. The introduction of new drugs like abiraterone and MDV3100 has shown that prostate cancer progression even in the"hormone-refractory" stage is driven by androgen receptor signaling. Based on this information the question of whether androgen deprivation therapy in castration-resistant prostate cancer should be continued or not is still of relevance. This review gives a critical overview of the literature and current guideline recommendations.

引用

页码：15 / +

页数：4

共 30 条

[11] THE RESPONSE OF METASTATIC ADENOCARCINOMA OF THE PROSTATE TO EXOGENOUS TESTOSTERONE [J].

FOWLER, JE ;

WHITMORE, WF .

JOURNAL OF UROLOGY, 1981, 126 (03) :372-375

[12] The current state of hormonal therapy for prostate cancer [J].

Hellerstedt, BA ;

Pienta, KJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (03) :154-179

[13] Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance [J].

Holzbeierlein, J ;

Lal, P ;

LaTulippe, E ;

Smith, A ;

Satagopan, J ;

Zhang, LY ;

Ryan, C ;

Smith, S ;

Scher, H ;

Scardino, P ;

Reuter, V ;

Gerald, WL .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :217-227

[14] EFFECTS OF CONTINUED ANDROGEN-DEPRIVATION THERAPY AND OTHER PROGNOSTIC FACTORS ON RESPONSE AND SURVIVAL IN PHASE-II CHEMOTHERAPY TRIALS FOR HORMONE-REFRACTORY PROSTATE-CANCER - A SOUTHWEST-ONCOLOGY-GROUP REPORT [J].

HUSSAIN, M ;

WOLF, M ;

MARSHALL, E ;

CRAWFORD, ED ;

EISENBERGER, M .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1868-1875

[15] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[16]

KELLY WK, 1993, J UROLOGY, V149, P607

[17] Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer [J].

Kelly, WK ;

Curley, T ;

Slovin, S ;

Heller, G ;

McCaffrey, J ;

Bajorin, D ;

Ciolino, A ;

Regan, K ;

Schwartz, M ;

Kantoff, P ;

George, D ;

Oh, W ;

Smith, M ;

Kaufman, D ;

Small, EJ ;

Schwartz, L ;

Larson, S ;

Tong, W ;

Scher, H .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :44-53

[18] ANDROGEN PRIMING AND CHEMOTHERAPY IN ADVANCED PROSTATE-CANCER - EVALUATION OF DETERMINANTS OF CLINICAL OUTCOME [J].

MANNI, A ;

BARTHOLOMEW, M ;

CAPLAN, R ;

BOUCHER, A ;

SANTEN, R ;

LIPTON, A ;

HARVEY, H ;

SIMMONDS, M ;

WHITEHERSHEY, D ;

GORDON, R ;

ROHNER, T ;

DRAGO, J ;

WETTLAUFER, J ;

GLODE, L .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1456-1466

[19] Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth [J].

Montgomery, R. Bruce ;

Mostaghel, Elahe A. ;

Vessella, Robert ;

Hess, David L. ;

Kalhorn, Thomas F. ;

Higano, Celestia S. ;

True, Lawrence D. ;

Nelson, Peter S. .

CANCER RESEARCH, 2008, 68 (11) :4447-4454

[20] EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer [J].

Mottet, Nicolas ;

Bellmunt, Joaquim ;

Bolla, Michel ;

Joniau, Steven ;

Mason, Malcolm ;

Matveev, Vsevolod ;

Schmid, Hans-Peter ;

Van der Kwast, Theo ;

Wiegel, Thomas ;

Zattoni, Filiberto ;

Heidenreich, Axel .

EUROPEAN UROLOGY, 2011, 59 (04) :572-583

← 1 2 3 →